ТАШКЕНТСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТКАФЕДРА ОНКОЛОГИИ И РАДИОЛОГИИ

Authors (1)

Abstract

Рак шейки матки является четвертым по распространенности видом рака у женщин во всем мире и приводит к более чем 300 000 смертей во всем мире. Возбудителем рака шейки матки является персистирующая инфекция, вызванная подтипами вируса папилломы человека высокого риска, а вирусные онкобелки E5, E6 и E7 взаимодействуют с факторами хозяина, вызывая и поддерживая злокачественный фенотип.

Cite this article

References

1. [1]Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229‐263. [DOI] [PubMed] [Google Scholar] 
2. [2]Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244‐265. [DOI] [PMC free article] [PubMed] [Google Scholar] 
3. [3]Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024;404(10451):435‐444. [DOI] [PubMed] [Google Scholar] 
4. [4]Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high‐risk area for cervical cancer. J Infect Dis. 1999;180:1415‐1423. [DOI] [PubMed] [Google Scholar] 
5. [5]Lycke KD, Steben M, Garland SM, et al. An updated understanding of the natural history of cervical human papillomavirus infection—clinical implications. Am J Obstet Gynecol. 2025;232(5):453‐460. doi: 10.1016/j.ajog.2025.02.029 [DOI] [PubMed] [Google Scholar] 
6. [6]World Health Organization . Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. WHO; 2020. Accessed December 17, 2024. https://www.who.int/publications/i/item/9789240014107 [Google Scholar] 18 TIBBIYOT AKADEMIYASI 4-SON 1-JILD APREL– 2026 1-QISM 
7. [7]Lei M, Zhao C, Zhao Y, Li J, Wei L. Immunogenicity, safety and efficacy of human papillomavirus vaccine: data from China. Front Immunol. 2024;14:1112750. [DOI] [PMC free article] [PubMed] [Google Scholar] 
8. [8]Sharma H, Parekh S, Pujari P, et al. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9‐14 years versus an established quadrivalent HPV vaccine in women aged 15‐26 years in India: a randomised, active‐controlled, multicentre, phase 2/3 trial. Lancet Oncol. 2023;24:1321‐1333. [DOI] [PubMed] [Google Scholar] 
9. [9]Bruni L, Albero G, Serrano B, et al. ICO/IARC. Information Centre on HPV and cancer (HPV information Centre). Human papillomavirus and related diseases in the world. Summary Report. March 10, 2023. Accessed December 2, 2024. https://hpvcentre.net/statistics/reports/XWX.pdf 
10. [10]World Health Organization . Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec No
11. [11]2022;97:645‐672. [Google Scholar] 
12. [12]World Health Organization . HPV Dashboard. Accessed December 21, 2024. https://www.who.int/teams/immunization‐vaccines‐and‐biologicals/diseases/human papillomavirus‐vaccines‐(HPV)/hpv‐clearing‐house/hpv‐dashboard 
13. [13]Kreimer AR, Watson‐Jones D, Kim JJ, Dull P. Single‐dose human papillomavirus vaccination: an update. JNCI Monogr. 2024;67:313‐413. Accessed December 21, 2024. https://academic.oup.com/jncimono/issue/2024/67 [DOI] [PMC free article] [PubMed] [Google Scholar] 
14. [14]Malvi S, Esmy PO, Muwonge R, et al. A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. JNCI Monogr. 2024;67:317‐328. [DOI] [PMC free article] [PubMed] [Google Scholar] 
15. [15]World Health Organization . Safety of HPV vaccines. Accessed December 21, 2024. https://www.who.int/groups/global‐advisory‐committee‐on‐vaccine‐safety/topics/human papillomavirus‐vaccines/safety/ 
16. [16]Torella M, Marrapodi MM, Ronsini C, et al. Risk of premature ovarian insufficiency after human papillomavirus vaccination: a PRISMA systematic review and meta‐analysis of current evidence. Vaccine. 2023;11(1):140. [DOI] [PMC free article] [PubMed] [Google Scholar] 
17. [17]Drolet M, Benard E, Perez N, et al. Population‐level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta‐analysis. Lancet. 2019;394:497‐509. [DOI] [PMC free article] [PubMed] [Google Scholar] 
18. [18]Lei J, Ploner A, Elfstrom M, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340‐1348. [DOI] [PubMed] [Google Scholar